The Advisory Committee on Immunization Practice (ACIP) has adopted and published recommendations regarding the use of cholera vaccine. Currently, Vaxchora (cholera vaccine, live, oral; ParVax) is the only vaccine available in the U.S. for active immunization against disease caused by Vibrio cholerae serogroup O1.

The recommendation states that U.S. adults (aged 18–64 years) who travel to an area of active cholera transmission should receive the vaccine. The vaccine is not routinely recommended for travelers who are not visiting areas of active cholera transmission. 

The efficacy of Vaxchora was studied in a randomized, placebo-controlled human challenge study (n=197) of U.S. volunteers aged 18–45 years old. Of the total volunteers, 68 Vaxchora recipients and 66 placebo recipients were challenged by oral ingestion of Vibrio cholerae. The efficacy of Vaxchora was 90% among those challenged 10 days post-vaccination, and 80% among those challenged 3 months post-vaccination. In addition, two studies to assess the immune system’s response to Vaxchora were conducted in adults aged 18–64. Among adults aged 18–45, 93% of Vaxchora recipients produced antibodies indicative of protection from cholera. Among adults aged 46–64, 90% produced antibodies indicative of protection from cholera.  

Related Articles

As data on the safety and efficacy of booster doses of Vaxchora are unavailable, and the duration of protection conferred by the primary dose beyond 3 months is unknown, a recommendation on the use of booster doses cannot be made at this time.  In addition, there is no available data on the safety and efficacy of the vaccine in children and adolescents <18 years of age or adults aged ≥65 years, in pregnant or breastfeeding women, or in immunocompromised populations.

The recommendations have been published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report.

For more information visit